血浆置换对慢加急性（亚急性）肝衰竭患者外周血CD34+细胞生物学活性的影响

吴贻琛; 姚红宇; 王开利; 姜祺予; 刘畅; 邢汉前; 刘素霞; 游绍莉; 赵军

doi:10.3969/j.issn.1001-5256.2018.11.023

血浆置换对慢加急性（亚急性）肝衰竭患者外周血CD34+细胞生物学活性的影响

DOI: 10.3969/j.issn.1001-5256.2018.11.023

1. 解放军第三〇二医院肝衰竭诊疗与研究中心
2. 解放军第三〇二医院临床数据中心
3. 河北大学公共卫生学院

详细信息

中图分类号: R575.3
计量
- 文章访问数: 358
- HTML全文浏览量: 50
- PDF下载量: 74
- 被引次数: 0
出版历程
- 出版日期: 2018-11-20

Effect of plasma exchange on bioactivity of peripheral blood CD34+ cells in patients with acute-on-chronic (subacute) liver failure

摘要

摘要:
目的研究慢加急性（亚急性）肝衰竭患者血浆置换前后机体内环境的改变对外周血CD34+细胞生物学活性的影响。方法采用含慢加急性（亚急性）肝衰竭患者血浆置换前后血清的培养基体外培养患者外周血CD34+细胞,通过比较2组细胞的生长曲线,及RT-PCR检测细胞表面标志物PK-M2、Integrin-β1、L-PK的表达,免疫荧光检测细胞表面标志Integrin-β1的表达情况,了解血浆置换后机体内环境的改善对外周血CD34+细胞生物学活性的影响。计量资料组间比较采用重复测量资料方差分析。结果血浆置换后组外周血CD34+细胞的增殖明显优于含血浆置换前血清培养组（P <0. 05）;血浆置换前组与血浆置换后组均能检测到PK-M2、Integrin-β1,未检测到L-PK。结论血浆置换对肝衰竭患者机体内环境的改善有利于维持外周血CD34+细胞的生物学活性,有助于提高干细胞移植治疗肝衰竭的疗效。
- 肝功能衰竭 /
- 抗原,CD34 /
- 血浆置换
Abstract:
Objective To investigate the effect of improvement in internal environment after plasma exchange on the bioactivity of peripheral blood CD34+cells in patients with acute-on-chronic ( subacute) liver failure. Methods The peripheral blood CD34+cells from patients with acute-on-chronic ( subacute) liver failure were cultured in vitro using the medium containing with the serum collected before or after plasma exchange. The growth curves of the two groups of cells were recorded and compared. RT-PCR was used to detect the expression of the cell surface markers PK-M2, Integrin-β1, and L-PK, and immunofluorescence was used to detect the expression of Integrin-β1. A repeated measures analysis of variance was used for comparison of continuous data between groups. Results The CD34+cells in the medium containing the serum collected after plasma exchange grew better than those in the medium containing the serum collected before plasma exchange ( P < 0. 05) . PK-M2 and Integrin-β1 were detected in the CD34+cells of both groups, but L-PK was not detected in either group. Conclusion For patients with liver failure, the improvement in internal environment after plasma exchange helps to maintain the bioactivity of peripheral blood CD34+cells, thus improving the efficacy of stem cell transplantation for liver failure.
- liver failure /
- antigens, CD34 /
- plasma exchange

HTML全文

参考文献(23)

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Disease, CMA; Severe Liver Disease and Artificial Liver Group, Chinese of Hepatology, CMA. Guideline for diagnosis and treatment of liver failure[J]. Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[2] PARK D, SYKES DB, SCADDEN DT. The hematopoietic stem cell niche[J]. Front Biosci (Landmark Ed) , 2012, 17:30-39.

[3] ABUSAMRA DB, ALEISA FA, AL-AMOODI AS, et al. Not just a marker:CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44[J]. Blood Adv, 2017, 1 (27) :2799-2816.

[4] DONG F, HAO S, GAO YD, et al. Research progress on the origin, mobilization, expansion and regulatory mechanisms of hematopoietic stem cells[J]. China Basic Sci, 2016, 18 (3) :7-12, 41. (in Chinese) 董芳, 郝莎, 高瀛岱, 等.造血干细胞发生、动员、扩增及内外调控机制研究的新进展[J].中国基础科学, 2016, 18 (3) :7-12, 41.

[5] FARHADFAR N, HOGAN WJ. Overview of the progress on haploidentical hematopoietic transplantation[J]. World J Transplant, 2016, 6 (4) :665-674.

[6] WANG XL, GE SD, MCNAMARA G, et al. Albumin-expressing hepatocyte-like cells develop in the livers of immune-deficient mice that received transplants of highly purified human hematopoietic stem cells[J]. Blood, 2003, 101 (10) :4200-4208.

[7] TAO YC, WANG ML, CHEN EQ, et al. Stem Cells Transplantation in the treatment of patients with liver failure[J]. Curr Stem Cell Res Ther, 2018, 13 (3) :193-201.

[8] QUARELLO P, TANDOI F, CARRARO F, et al. Successful sequential liver and hematopoietic stem cell transplantation in a child with CD40 ligand deficiency and cryptosporidium-induced liver cirrhosis[J]. Transplantation, 2018, 102 (5) :823-828.

[9] DUAN XZ, XIN SJ. An update on cell therapy of liver failure:Bench to bedside[J]. Infect Dis Info, 2011, 24 (3) :132-135. (in Chinese) 段学章, 辛绍杰.肝衰竭的细胞治疗:距离临床有多远?[J].传染病信息, 2011, 24 (3) :132-135.

[10] WINTERS JL. Plasma exchange:Concepts, mechanisms, and an overview of the American Society for Apheresis guidelines[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012:7-12.

[11] HONG H, CHEN JZ, ZHOU F. Influence of serum from liverdamaged rats on differentiation tendency of bone marrow-derived stem cells[J]. World J Gastroenterol, 2004, 10 (15) :2250-2253.

[12] COUVELARD A, BRINGUIER AF, DAUGE MC, et al. Expression of integrins during liver organogenesis in humans[J]. Hepatology, 1998, 27 (3) :839-847.

[13] LIU XH, GUO HQ, ZHANG J, et al. Progress in technology and clinical application of non-bioartificial liver support system[J]. J Clin Hepatol, 2013, 29 (9) :661-665. (in Chinese) 刘晓慧, 郭海清, 张晶, 等.非生物型人工肝技术及其临床应用新进展[J].临床肝胆病杂志, 2013, 29 (9) :661-665.

[14] LI SS, DUAN ZP, CHEN Y. New ideas and methods for the diagnosis and treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34 (4) :877-882. (in Chinese) 李珊珊, 段钟平, 陈煜.慢加急性肝衰竭诊治新思路与新方法[J].临床肝胆病杂志, 2018, 34 (4) :877-882.

[15] HAM Y, CUI LN, GUO GY. Immunotherapy for acute-on-chronic liver failure[J]. J Clin Hepatol, 2017, 33 (9) :1677-1682. (in Chinese) 韩英, 崔丽娜, 郭冠亚.慢加急性肝衰竭的免疫治疗[J].临床肝胆病杂志, 2017, 33 (9) :1677-1682.

[16] SONG YY, CHEN XR, LYU X, et al. Research progress in effect of mesenchymal stem cells in treatment of diabetes mellitus related diseases[J]. J Jilin Univ:Med Edit, 2017, 43 (3) :656-658. (in Chinese) 宋媛媛, 陈香润, 吕欣, 等.间充质干细胞对糖尿病相关病变治疗作用的研究进展[J].吉林大学学报, 医学版, 2017, 43 (3) :656-658.

[17] SHI XY, LIU YE, ZHANG YB. et al. Research progress of stem cell therapy for radiation brain injury[J]. Trauma and Crit Medicine, 2017, 5 (5) :302-305. (in Chinese) 史秀云, 柳云恩, 张玉彪, 等.干细胞治疗放射性脑损伤的研究进展[J].创伤与急危重病医学, 2017, 5 (5) :302-305.

[18] TAN J, WU W, CAMILLO R, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants:A randomized controlled trial[J]. JAMA, 2012, 307 (11) :1169-1177.

[19] MATHIEU E, LAMIRAULT G, TOQUET C, et al. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction[J]. PLo S One, 2011, 7 (12) :e51991.

[20] CONNICK P, KOLAPPAN M, CRAWLEY C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis:An open-label phase 2a proof-of-concept study[J]. Lancet Neurol, 2012, 11 (2) :150-156.

[21] YANG HZ, DUAN XZ, LIU XY, et al. Evaluation of the safety of granulocyte colony-stimulating factor subcutaneous injection as treatment for HBV-related acute on chronic liver failure[J]. Chin J Hepatol, 2015, 23 (5) :378-380. (in Chinese) 杨昊臻, 段学章, 刘晓燕, 等.皮下注射重组人粒细胞集落刺激因子治疗HBV相关慢加急性肝衰竭的安全性研究[J].中华肝脏病杂志, 2015, 23 (5) :378-380.

[22] WU YC, WAN ZH, RONG YH, et al. Bioactivity of CD34+cells in patients with acute-on-chronic liver failure[J]. Int J Clin Exp Pathol, 2017, 10 (11) :10781-10791.

[23] WANG JB, GE DY, LI XY, et al. Hepatic failure patient's serum before and after plasmapheresis induces the differentiation of umbilical cord mesenchymal stem cells into hepatic cells[J]. Chin J Tissue Engineer Res, 2017, 21 (17) :2659-2664. (in Chinese) 王晶波, 耿大影, 李晓迎, 等.肝衰竭患者血浆置换前后血清诱导脐带间充质干细胞向肝细胞的分化[J].中国组织工程研究, 2017, 21 (17) :2659-2664.

施引文献

资源附件(0)

访问统计